FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383550489> ?p ?o ?g. }

• W4383550489 abstract "Abstract Background The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and European participants using samples obtained from three international clinical trials. Methods/Principal Findings We conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EVD in children, adolescents and adults from the United Kingdom, France, Burkina Faso, Cote d’Ivoire, Kenya, Uganda and Sierra Leone. Immune markers of helminth exposure at baseline were evaluated by ELISA with three commercial kits which detect IgG antibodies against schistosome, filarial and Strongyloides antigens. Luminex technology was used to measure inflammatory and activation markers, and Th1/Th2/Th17 cytokines at baseline. The association between binding IgG antibodies specific to EBOV GP (measured on day 21 post-dose 2 and on Day 365 after the first dose respectively), and helminth exposure at baseline was evaluated using a multivariable linear regression model adjusted for age and study group. Seventy-eight (21.3%) of the 367 participants included in the study had at least one helminth positive ELISA test at baseline, with differences of prevalence between studies and an increased prevalence with age. The most frequently detected antibodies were those to Schistosoma mansoni (10.9%), followed by Acanthocheilonema viteae (9%) and then Strongyloides ratti (7.9%). Among the 41 immunological analytes tested, five were significantly (p<.003) lower in participants with at least one positive helminth ELISA test result: CCL2/MCP1, FGFbasic, IL-7, IL-13 and CCL11/Eotaxin compared to participants with negative helminth ELISA tests. No significant association was found with EBOV-GP specific antibody concentration at 21 days post-dose 2, or at 365 days post-dose 1, adjusted for age group, study, and the presence of any helminth antibodies at baseline. Conclusions/Significance No clear association was found between immune markers of helminth exposure as measured by ELISA and post-vaccination response to the Ebola Ad26.ZEBOV/ MVA- BN-Filo vaccine regimen. Author Summary Recurrent exposure to parasites may influence the immune response to vaccines, especially in endemic African countries. In this study we aimed to assess the association between immune markers of helminth exposure and the immune response post-vaccination with the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in African and European participants who participated in three international clinical trials. Seventy-eight (21.3%) of the 367 participants included in the study, had at least one helminth ELISA positive test at baseline with differences of prevalence between studies and an increased prevalence with increasing age. After adjustment for confounding factors, the study did not show a clear association between immunological markers of helminth exposure and the antibody concentration in response to the Ebola vaccine regimen." @default.
• W4383550489 created "2023-07-08" @default.
• W4383550489 creator A5002994916 @default.
• W4383550489 creator A5004888274 @default.
• W4383550489 creator A5015870296 @default.
• W4383550489 creator A5022077216 @default.
• W4383550489 creator A5027270405 @default.
• W4383550489 creator A5028786354 @default.
• W4383550489 creator A5030863765 @default.
• W4383550489 creator A5031897523 @default.
• W4383550489 creator A5041520820 @default.
• W4383550489 creator A5069437397 @default.
• W4383550489 creator A5075916576 @default.
• W4383550489 creator A5085554677 @default.
• W4383550489 creator A5091028608 @default.
• W4383550489 date "2023-07-06" @default.
• W4383550489 modified "2023-10-18" @default.
• W4383550489 title "Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen" @default.
• W4383550489 cites W1986836020 @default.
• W4383550489 cites W1987726837 @default.
• W4383550489 cites W1998033651 @default.
• W4383550489 cites W2006930490 @default.
• W4383550489 cites W2016150993 @default.
• W4383550489 cites W2023771969 @default.
• W4383550489 cites W2034645256 @default.
• W4383550489 cites W2050592364 @default.
• W4383550489 cites W2059442842 @default.
• W4383550489 cites W2065076563 @default.
• W4383550489 cites W2145590827 @default.
• W4383550489 cites W2152776307 @default.
• W4383550489 cites W2302175155 @default.
• W4383550489 cites W2342023283 @default.
• W4383550489 cites W2417247633 @default.
• W4383550489 cites W2753060146 @default.
• W4383550489 cites W2801770772 @default.
• W4383550489 cites W2883650593 @default.
• W4383550489 cites W2913764791 @default.
• W4383550489 cites W2917849476 @default.
• W4383550489 cites W2921553057 @default.
• W4383550489 cites W2924137075 @default.
• W4383550489 cites W2930141921 @default.
• W4383550489 cites W2949515262 @default.
• W4383550489 cites W2967823810 @default.
• W4383550489 cites W3003277043 @default.
• W4383550489 cites W3099517149 @default.
• W4383550489 cites W3199739238 @default.
• W4383550489 cites W3200905140 @default.
• W4383550489 cites W3209728196 @default.
• W4383550489 cites W4205961845 @default.
• W4383550489 cites W4206655662 @default.
• W4383550489 cites W4226020952 @default.
• W4383550489 cites W4285740436 @default.
• W4383550489 cites W4308231345 @default.
• W4383550489 cites W4321595852 @default.
• W4383550489 doi "https://doi.org/10.1101/2023.07.05.23292287" @default.
• W4383550489 hasPublicationYear "2023" @default.
• W4383550489 type Work @default.
• W4383550489 citedByCount "0" @default.
• W4383550489 crossrefType "posted-content" @default.
• W4383550489 hasAuthorship W4383550489A5002994916 @default.
• W4383550489 hasAuthorship W4383550489A5004888274 @default.
• W4383550489 hasAuthorship W4383550489A5015870296 @default.
• W4383550489 hasAuthorship W4383550489A5022077216 @default.
• W4383550489 hasAuthorship W4383550489A5027270405 @default.
• W4383550489 hasAuthorship W4383550489A5028786354 @default.
• W4383550489 hasAuthorship W4383550489A5030863765 @default.
• W4383550489 hasAuthorship W4383550489A5031897523 @default.
• W4383550489 hasAuthorship W4383550489A5041520820 @default.
• W4383550489 hasAuthorship W4383550489A5069437397 @default.
• W4383550489 hasAuthorship W4383550489A5075916576 @default.
• W4383550489 hasAuthorship W4383550489A5085554677 @default.
• W4383550489 hasAuthorship W4383550489A5091028608 @default.
• W4383550489 hasBestOaLocation W43835504891 @default.
• W4383550489 hasConcept C126322002 @default.
• W4383550489 hasConcept C159654299 @default.
• W4383550489 hasConcept C162324750 @default.
• W4383550489 hasConcept C203014093 @default.
• W4383550489 hasConcept C22070199 @default.
• W4383550489 hasConcept C2522874641 @default.
• W4383550489 hasConcept C2777469322 @default.
• W4383550489 hasConcept C2778933410 @default.
• W4383550489 hasConcept C2781413609 @default.
• W4383550489 hasConcept C3018567284 @default.
• W4383550489 hasConcept C47768531 @default.
• W4383550489 hasConcept C71924100 @default.
• W4383550489 hasConcept C8891405 @default.
• W4383550489 hasConceptScore W4383550489C126322002 @default.
• W4383550489 hasConceptScore W4383550489C159654299 @default.
• W4383550489 hasConceptScore W4383550489C162324750 @default.
• W4383550489 hasConceptScore W4383550489C203014093 @default.
• W4383550489 hasConceptScore W4383550489C22070199 @default.
• W4383550489 hasConceptScore W4383550489C2522874641 @default.
• W4383550489 hasConceptScore W4383550489C2777469322 @default.
• W4383550489 hasConceptScore W4383550489C2778933410 @default.
• W4383550489 hasConceptScore W4383550489C2781413609 @default.
• W4383550489 hasConceptScore W4383550489C3018567284 @default.
• W4383550489 hasConceptScore W4383550489C47768531 @default.
• W4383550489 hasConceptScore W4383550489C71924100 @default.
• W4383550489 hasConceptScore W4383550489C8891405 @default.
• W4383550489 hasLocation W43835504891 @default.

• next